This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MET vs. ZURVY: Which Stock Is the Better Value Option?
by Zacks Equity Research
MET vs. ZURVY: Which Stock Is the Better Value Option?
Is MetLife (MET) Outperforming Other Finance Stocks This Year?
by Zacks Equity Research
Here is how MetLife (MET) and Popular (BPOP) have performed compared to their sector so far this year.
Is MetLife (MET) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Analyzing MetLife Stock: Is Buy Strategy the Right Move?
by Zacks Equity Research
MET remains well-poised for growth, attributed to strength in the EMEA segment, divestiture of underperforming businesses and a commendable financial stand.
Are Investors Undervaluing CNO Financial Group (CNO) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are You Looking for a High-Growth Dividend Stock?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
Zacks Industry Outlook Highlights MetLife, American International Group, Prudential Financial, Assurant and MGIC Investment
by Zacks Equity Research
MetLife, American International Group, Prudential Financial, Assurant and MGIC Investment are part of the Zacks Industry Outlook article.
5 Stocks to Watch From the Prospering Multiline Insurance Industry
by Tanuka De
Better pricing, product redesigns, technological advancement, and improving inflation are expected to aid multiline insurers like MET, AIG, PRU, AIZ and MTG.
Top Stock Reports for NVIDIA, AT&T & Lockheed Martin
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), AT&T Inc. (T) and Lockheed Martin Corporation (LMT), as well as two micro-cap stocks Steel Partners Holdings L.P. (SPLP) and Natural Resource Partners L.P. (NRP).
Prudential Financial Lags Industry: Is the Stock a Hold or Fold?
by Tanuka De
Investors who already have PRU stock in their portfolio should retain it as this insurance behemoth is unlikely to disappoint.
Hanover Insurance Group Stock Near 52-Week High: Time to Buy?
by Tanuka De
THG stands to gain from growth in the Core Commercial and Specialty segments, stable retention, better pricing, strong market presence and solid capital position.
Trupanion Stock Near 52-Week High: Time to Buy or Hold?
by Tanuka De
TRUP is poised to grow on its focus on pet health and well-being in an underpenetrated pet insurance market, product launches, extended operating boundaries and a solid capital position.
Here's Why MetLife (MET) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why MetLife (MET) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
Why MetLife (MET) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
MetLife (MET) Q2 Earnings Beat on Favorable Underwriting Results
by Zacks Equity Research
MetLife's (MET) second-quarter 2024 results benefit from improved variable investment income, strong volumes and strength in the Group Benefits segment. However, poor performance in the RIS segment partially offset the results.
Here's What Key Metrics Tell Us About MetLife (MET) Q2 Earnings
by Zacks Equity Research
The headline numbers for MetLife (MET) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MetLife (MET) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
MetLife (MET) delivered earnings and revenue surprises of 7.04% and 2.69%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Q2 Beat or Miss: What's Ahead for These 5 Insurance Stocks?
by Kaibalya Pravo Dey
Improving business environment, underwriting practices and other factors are expected to have benefited insurance players in the second quarter. MET, AFL, AIG, ALL and EG will release earnings on Jul 31.
Can MetLife (MET) Tackle Lower Premiums in Q2 Earnings?
by Zacks Equity Research
MetLife's (MET) Q2 results are likely to benefit from growing net investment income and a well-performing Latin America segment, partly offset by a fall in overall premiums.
Stay Ahead of the Game With MetLife (MET) Q2 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of MetLife (MET) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
MetLife (MET) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
MetLife (MET) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
MetLife (MET) Arm MIM Secures $1.2B for 2nd Private Equity Fund
by Zacks Equity Research
MetLife (MET) Arm, MIM, plans to utilize $250 million on new private equity opportunities.
MetLife (MET), GeoBlue Unveil Globaline for Expatriate Benefits
by Zacks Equity Research
MetLife (MET) and GeoBlue launch Globaline, a comprehensive expatriate benefits solution, offering unified medical and ancillary coverage, leveraging extensive global health networks for seamless support.